Archives of Pediatric Infectious Diseases

Published by: Kowsar
Crossmark

Hepatitis B Seroconversion Rate After Primary Immunization Series with Newly Introduced Pentavalent Vaccine: A Report of Local Study in Alborz Province, Iran, 2016

Reza Arjmand 1 , Mehri Golami 2 , Fariba Shirvani 3 , * , Kumars Pourrostami 1 , Omid Safari 1 , Nasrin Elahimehr 1 , Saeed Nikkhah 1 , Ehsan Zahmatkesh 1 , Mostafa Qorbani 4 and Esfandiar Najafi Tavana 1
Authors Information
1 Department of Pediatric, Emam Ali Hospital, Alborz University of Medical Sciences, Karaj, Iran
2 Alborz University of Medical Sciences, Karaj, Iran
3 Pediatric Infections Research Center, Research Institute for Children's Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran
4 Non-Communicable Diseases Research Center, Alborz University of Medical Sciences, Karaj, Iran
Article information
  • Archives of Pediatric Infectious Diseases: April 30, 2019, 7 (2); e83565
  • Published Online: April 13, 2019
  • Article Type: Research Article
  • Received: August 24, 2018
  • Revised: March 10, 2019
  • Accepted: March 11, 2019
  • DOI: 10.5812/pedinfect.83565

To Cite: Arjmand R, Golami M, Shirvani F, Pourrostami K , Safari O, et al. Hepatitis B Seroconversion Rate After Primary Immunization Series with Newly Introduced Pentavalent Vaccine: A Report of Local Study in Alborz Province, Iran, 2016, Arch Pediatr Infect Dis. 2019 ; 7(2):e83565. doi: 10.5812/pedinfect.83565.

Abstract
Copyright © 2019, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Zanetti AR, Van Damme P, Shouval D. The global impact of vaccination against hepatitis B: A historical overview. Vaccine. 2008;26(49):6266-73. doi: 10.1016/j.vaccine.2008.09.056. [PubMed: 18848855].
  • 2. World Health Organization. Hepatitis B, Key facts. World Health Organization; 5 july 2017. Available from: http://www.who.int/news-room/fact-sheets/detail/hepatitis-b.
  • 3. MacLachlan JH, Locarnini S, Cowie BC. Estimating the global prevalence of hepatitis B. Lancet. 2015;386(10003):1515-7. doi: 10.1016/S0140-6736(15)61116-3. [PubMed: 26231458].
  • 4. World Health Organization. Hepatitis B fact sheet. World Health Organization; 18 july2018. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-b.
  • 5. Schonberger K, Riedel C, Ruckinger S, Mansmann U, Jilg W, Kries RV. Determinants of Long-term protection after hepatitis B vaccination in infancy: A meta-analysis. Pediatr Infect Dis J. 2013;32(4):307-13. doi: 10.1097/INF.0b013e31827bd1b0. [PubMed: 23249904].
  • 6. Poorolajal J, Mahmoodi M, Majdzadeh R, Nasseri-Moghaddam S, Haghdoost A, Fotouhi A. Long-term protection provided by hepatitis B vaccine and need for booster dose: A meta-analysis. Vaccine. 2010;28(3):623-31. doi: 10.1016/j.vaccine.2009.10.068. [PubMed: 19887132].
  • 7. Kabir A, Alavian SM, Ahanchi N, Malekzadeh R. Combined passive and active immunoprophylaxis for preventing perinatal transmission of the hepatitis B virus in infants born to HBsAg positive mothers in comparison with vaccine alone. Hepatol Res. 2006;36(4):265-71. doi: 10.1016/j.hepres.2006.08.001. [PubMed: 16965939].
  • 8. Lankarani KB, Taghavi AR, Agah S, Karimi A. Comparison of intradermal and intramuscular administration of hepatitis B vaccine in neonates. Indian J Gastroenterol. 2001;20(3):94-6. [PubMed: 11400817].
  • 9. Hassan S, Ziba F. Antibody titer in Iranian children 6 years after hepatitis B vaccine administration. Vaccine. 2007;25(17):3511-4. doi: 10.1016/j.vaccine.2005.09.037. [PubMed: 17400337].
  • 10. Hadi N, Hadi N. Assessment of anti-HBs antigen in 6- to 9-year-old children routinely vaccinated via vaccination program in Iran. Med Princ Pract. 2007;16(4):306-9. doi: 10.1159/000102154. [PubMed: 17541297].
  • 11. Adibi P, Ghassemian R, Alavian SM, Ranjbar M, Mohammadalizadeh AH, Nematizadeh F, et al. Effectiveness of hepatitis B vaccination in children of chronic hepatitis B mothers. Saudi Med J. 2004;25(10):1414-8. [PubMed: 15494813].
  • 12. Saffar MJ, Rezai MS. Long-term antibody response and immunologic memory in children immunized with hepatitis B vaccine at birth. Indian Pediatr. 2004;41(12):1232-7. [PubMed: 15623904].
  • 13. Tazhibi M, Hajivandi A, Tafti AD, Fallahzadeh H. The efficacy of hepatitis B vaccine in Iranian population: A systematic review and meta-analysis. J Educ Health Promot. 2014;3:53. doi: 10.4103/2277-9531.134741. [PubMed: 25077146]. [PubMed Central: PMC4114169].
  • 14. Saffar H, Ajami A, Saffar MJ, Shojaei J, Sotudeh-Anvari M, Shams-Esfandabad K, et al. Prevalence of hepatitis B virus seromarkers in young adults vaccinated at birth; impact on the epidemiology of hepatitis B infection in iran. Hepat Mon. 2014;14(5). e17263. doi: 10.5812/hepatmon.17263. [PubMed: 24829589]. [PubMed Central: PMC4013494].
  • 15. Dahifar H. Immunogenecity of cuban hepatitis B vaccine in Iranian children. Arch Iranian Med. 2004;7(2):89-92.
  • 16. Rostami N, Ghaffari V, Samaie H. Comparison of immune response to hepatitis B vaccine between term and preterm infants at birth. Arch Clin Infect Dis. 2006;7(1):11-4.
  • 17. Moradi A, Khodabakhshi B, Ghaemi E, Mansourian AR, Sarikhani A, Saeidi M. [The response rate to hepatitis B vaccine in under one-year children in Gorgan, Iran]. J GorganUni Med Sci. 2008;10(2):50-3. Persian.
  • 18. Huu TN, Phuong NT, Toan NT, Thang HV. Immunogenicity and safety of quinvaxem(R) (diphtheria, tetanus, whole-cell pertussis, hepatitis B and haemophilus influenzae type B vaccine) given to vietnamese infants at 2 to 4 months of age. Southeast Asian J Trop Med Public Health. 2015;46(4):753-63. [PubMed: 26867396].
  • 19. Schillie SF, Murphy TV. Seroprotection after recombinant hepatitis B vaccination among newborn infants: A review. Vaccine. 2013;31(21):2506-16. doi: 10.1016/j.vaccine.2012.12.012. [PubMed: 23257713].
  • 20. Eregowda A, Lalwani S, Chatterjee S, Vakil H, Ahmed K, Costantini M, et al. A phase III single arm, multicenter, open-label study to assess the immunogenicity and tolerability of a pentavalent DTwP-HepB-Hib vaccine in indian infants. Hum Vaccin Immunother. 2013;9(9):1903-9. doi: 10.4161/hv.25166. [PubMed: 23783081]. [PubMed Central: PMC3906354].
  • 21. Rezaee R, Aghcheli B, Poortahmasebi V, Qorbani M, Alavian SM, Jazayeri SM. Prevalence of national responsiveness to HBV vaccine after 22 years of Iranian Expanded Program on Immunization (EPI): A systematic review and meta-analysis study. Hepat Mon. 2015;15(5). e23618. doi: 10.5812/hepatmon.15(04)2015.23618. [PubMed: 26045701]. [PubMed Central: PMC4451270].
  • 22. Najafi F, Sayehmiri K, Najafi R. Efficacy of hepatitis B vaccination in under five-year-old children in Iran: A systematic review and meta-analysis study. Hepat Mon. 2018;18(6). e65385. doi: 10.5812/hepatmon.65385.
  • 23. Von Kriesa R, Kaliesa H, Schmittb HJ. DTPa (+)/Hib combination vaccines: The German experience. Anals De Pediatria. 2003;58(S5.21).
  • 24. Verma C, Faridi MM, Narang M, Kaur IR. Anti-HBs titers following pentavalent immunization (DTwP-HBV-Hib) in term normal weight vs low birthweight infants. Indian Pediatr. 2018;55(5):395-9. [PubMed: 29428913].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments